3 Australian Healthcare Stocks With Revenue Growth Up To 38%

Healthcare shares have drawn fresh attention after the recent US midterm results shook Wall Street and investors rotated toward sectors seen as more defensive, including healthcare. For Australian investors, that puts established local medical businesses with solid balance sheets in the spotlight. This article walks through three leading Australian healthcare stocks from our screener and explains what sets each one apart right now.

The three healthcare stocks covered next are only a sample, and the full screen surfaced 9 more Australian healthcare companies with equally compelling stories that are not included in this article. To see the broader opportunity set, head straight to the Best Healthcare Stocks screener to identify, filter, and analyze the highest conviction ideas in this theme.

Cochlear (ASX:COH)

Cochlear is a pure play on implantable hearing solutions, with its cochlear implant systems, sound processors and connected care tools placing it squarely in the Best Healthcare Stocks theme.

Cochlear generates all of its A$2.3b in revenue from implantable hearing devices and related services, and the stock is valued at about A$10.2b.

"The launch of the Nexa system, the world's first smart cochlear implant, is now reflected in more than 95% of developed market implant sales and around a 3% price uplift."

What happens to margins and growth if a single pressure point on pricing and product mix moves in the right direction?

If that pricing lever really starts to move, read the full narrative for Cochlear to see what could be accelerating beneath Cochlear's headline numbers.

Mesoblast (ASX:MSB)

Mesoblast focuses on regenerative medicine, using mesenchymal lineage cell therapies such as Ryoncil and Remestemcel L to target inflammatory and cardiovascular conditions. It currently earns about US$120 million from developing and commercializing this platform, with the stock valued around A$2.6b.

Mesoblast gives the Best Healthcare Stocks theme a pure biotech angle, with products already in use and late stage programs extending into cardiovascular disease and chronic pain.

"The first and only FDA approved mesenchymal stromal cell product in the U.S., Ryoncil, together with over 1,100 patents and established commercial scale manufacturing, positions Mesoblast to benefit if cell therapies gain wider medical adoption."

The key issue now is how any pivotal change in treatment habits may influence demand, pricing power and the pace of any transition into sustained earnings.

If that transition is what you are watching, read the full narrative for Mesoblast to see where Mesoblast's risk, catalyst timing and competitive position may be decoupling.

Neuren Pharmaceuticals (ASX:NEU)

Neuren Pharmaceuticals focuses on therapies for rare neurological conditions, anchored by DAYBUE for Rett syndrome, and generated A$69.5 million from commercial products, giving it a direct link to the Best Healthcare Stocks theme at a market value of about A$2.9b.

Neuren Pharmaceuticals gives this healthcare screen a pure neurology angle, with DAYBUE already on the market and a follow on pipeline aimed at several other rare childhood disorders. This is where the next phase of its story starts to get interesting.

"Planned expansion into international markets, such as Canada, Europe, and Japan, offers significant long-term growth prospects and additional revenue streams due to higher royalty rates outside the U.S."

The real swing factor is what happens if a single assumption about how much of that future royalty flow turns into durable profit margins shifts.

If that shift in profitability is what you are tracking, read the full narrative for Neuren Pharmaceuticals to see where Neuren Pharmaceuticals' royalty engine might be quietly accelerating.

Seeking Fresh Alternatives Beyond Healthcare?

Some opportunities start to break out while most investors are still distracted. Fresh ideas can pick up momentum fast, then get caught once the crowd arrives, so consider acting early if they fit your strategy.

• Spot cash generative businesses before the story goes mainstream by scanning the 3 high quality undervalued stocks while it matters and before pricing fully reflects their strength.
• Review the curated 52 AI infrastructure stocks to follow infrastructure trends that support AI workloads and track which operators are building the backbone of future computing.
• Explore early movers in robotics by filtering through the hand picked 90 robotics and automation stocks that are reshaping automation on factory floors and beyond.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com